ivermectin for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. chloroquine and derivatives
vs. hydroxychloroquine
vs. hydroxychloroquine plus macrolides
vs. lopinavir/ritonavir
vs. control
vs. placebo
vs. standard of care
vs. Vitamins
vs. vitamin C

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 1

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

Galan, 2021 RBR-8h7q82

ivermectin (n=53) vs. chloroquine (n=115)

randomized controlled trial

Studied treatment

Ivermectin
14 mg once at day 0 1 placebo tablet at day 0, and once daily from day 1 to day 2, 1 placebo tablet daily from day 3 to 4, total dose 42 mg

Control treatment

Hydroxychloroquine or Chloroquine
HCQ : 400 mg twice on day 0, and once daily from day 1 to day 4, total dose 2.4 gCQ : 450 mg, twice on day 0, and once daily from day 1 to day 4, total dose 2.7 g

3 arms: chloroquine, hydroxychloroquine, ivermectin.

Patients

COVID-19 severe or critically

Method

Double-blind.

Single center, Brasil.

Phase II.

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open